Exagen stock gains 3.55 percent as Q2 growth nears breakeven
Published on 10/05/2026 at 23:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exagen stock (ISIN US30068X1037) was last at USD 8.46 on Nasdaq on October 5, 2026, up 3.55 percent, while the diagnostics company advances toward adjusted EBITDA breakeven. In Q2 2026, revenue reached USD 19.94 million, beating the USD 17.80 million consensus estimate, according to MarketBeat.
Revenue reaches a record
Exagen's Q2 revenue rose 16 percent from the same period a year earlier, while adjusted EBITDA loss narrowed to USD 0.1 million from USD 1.7 million. Benzinga reported that management also highlighted record AVISE CTD test volume and a trailing 12-month average selling price of USD 446 per test.
The GAAP diluted loss was USD 0.13 per share in Q2 2026, compared with a consensus loss of USD 0.19, a USD 0.06 improvement against expectations. Gross margin reached 61 percent, according to Exagen's Q2 earnings-call discussion carried by Benzinga.
Guidance moves higher
Exagen raised its full-year 2026 revenue guidance to USD 72 million to USD 75 million from USD 70 million to USD 73 million. Management said the outlook reflects first-half execution, high single-digit volume growth and mid-single-digit average selling price growth.
The operating threshold is clear: management expects adjusted EBITDA breakeven at USD 80 million in annual revenue. The company also plans to commercialize its Myositis offering in early 2027, adding a product expansion angle to the current AVISE diagnostics business.
Analyst target remains above price
MarketBeat reported a Moderate Buy consensus from nine analysts, with seven Buy ratings, one Strong Buy rating and one Sell rating. The average 12-month target of USD 9.625 lies 13.8 percent above the October 5 price of USD 8.46, while published targets span USD 8 to USD 12.
Stock trades below yearly high
XGN was last at USD 8.46 on Nasdaq on October 5, 2026, with a session range of USD 8.03 to USD 8.54 and volume of 291,762 shares. Its 52-week range was USD 2.59 to USD 12.23, leaving the price 30.8 percent below the high.
Exagen stock facts
- Company: Exagen Inc.
- ISIN: US30068X1037
- Ticker: XGN
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 4:00 p.m. ET): USD 8.46
- Market capitalization: USD 204.4 million (as of October 5, 2026)
- 52-week range: USD 2.59-USD 12.23 (as of October 5, 2026)
- Sector / Industry: Healthcare Facilities & Services
